Liver News and Research

RSS

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Results from two significant Canadian studies underscore the growing scientific evidence of PEGETRON's positive outcomes in the treatment of chronic hepatitis C virus (HCV) infection. Canadian investigators across the country collaborated to generate and analyze clinical data from the Canadian PEGETRON POWeR (Prospective Optimal Weight-based Dosing Response) and REDIPEN programs, which were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston on November 1, 2009.

2 Nov 2009

Methacetin breath test predicts long-term survival in patients with chronic viral hepatitis

A methacetin breath test (MBT) that can be performed quickly and noninvasively has been proven to accurately predict survival in patients with viral hepatitis and may be used as an adjunctive tool to MELD.

2 Nov 2009

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.

2 Nov 2009

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

2 Nov 2009

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

2 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Study finds no link between hepatitis B and pancreatic cancer

A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.

2 Nov 2009

HCV progresses more rapidly after liver transplantation in African-Americans compared to whites

Previous studies have shown that hepatitis C virus (HCV) progresses slower prior to liver transplantation in African Americans than in whites. However, researchers demonstrate in this study, which will be presented at the annual meeting of the American Association for the Study of Liver Diseases, that the opposite is true after transplantation, in that recurrent HCV in the transplanted liver progresses faster in African Americans than in whites.

1 Nov 2009

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

31 Oct 2009

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

31 Oct 2009

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Researchers in New York City are reporting their work uncovering a new epidemic of hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) who have HIV infection.

30 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Idenix Pharmaceuticals, Inc.a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in Boston, Massachusetts.

30 Oct 2009

Left side grafting has lower risk to donors; small graft size not the only cause of 'small-for-size graft syndrome'

A recent study by doctors at Shinshu University, School of Medicine, in Japan determined that left side grafting has lower risk to donors compared to grafts taken from the right lobe, and it appears to be the procedure of choice for adult-to-adult living donor liver transplantation (LDLT).

30 Oct 2009

Repros Therapeutics signs settlement agreement with major creditors

Repros Therapeutics today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program.

30 Oct 2009

Dr. Chao Herbal Drink Line releases two all-natural, vegan beverages

The Dr. Chao Herbal Drink Line released two all-natural, vegan beverages to enhance sexual health and combat premenstrual symptoms. The new Adult and Lady drinks have no sugar, artificial sweeteners or preservatives, glutens, and caffeine, do not require costly prescriptions and have health benefits derived from the recipes of a 19th-century Chinese herbalist.

30 Oct 2009

Liver News and Research

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Methacetin breath test predicts long-term survival in patients with chronic viral hepatitis

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Gilead Sciences to present Viread Phase III clinical trial data

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Study finds no link between hepatitis B and pancreatic cancer

HCV progresses more rapidly after liver transplantation in African-Americans compared to whites

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Left side grafting has lower risk to donors; small graft size not the only cause of 'small-for-size graft syndrome'

Repros Therapeutics signs settlement agreement with major creditors

Dr. Chao Herbal Drink Line releases two all-natural, vegan beverages

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News